Autonomyo launches crowdfunding to scale home-based robotic rehabilitation

Autonomyo aims to address one of the most pressing challenges in neurological rehabilitation: access to intensive, repeatable gait training. Each year, more than 15 million people worldwide suffer a stroke, and up to half of them leave rehabilitation without regaining independent walking ability. This gap is not only due to medical limitations but also to the restricted availability, high cost and limited intensity of traditional rehabilitation programs.

Autonomyo’s technology was developed within EPFL’s REHAssist laboratory and refined through clinical collaborations in Western Switzerland. Its flagship product, Skywalk, is described as the world’s first intelligent safety frame enabling safe, assisted gait training outside clinical environments. By stabilizing users and preventing falls, Skywalk allows patients to practise walking more frequently and more confidently.

The system integrates with Autonomyo’s AI-assisted lower-limb exoskeleton, which guides hip, knee and ankle movement, while collecting biomechanical data to personalize training. A connected digital platform enables therapists to monitor progress remotely, adapt exercise plans and support long-term recovery. Together, these components aim to make rehabilitation accessible, continuous and affordable, whether in clinics, physiotherapy practices or at home.

Autonomyo has already completed successful clinical trials at CHUV, validating both the safety and therapeutic potential of its technology. The company is now preparing CE marking and FDA readiness for 2025.

Funding to accelerate industrialization and international deployment

The EUR 1.4 million recently raised will allow Autonomyo to scale production of Skywalk and its third-generation exoskeleton, strengthen its digital rehabilitation content, and prepare for broader commercial introduction. The parallel crowdfunding campaign invites the public to contribute to the company’s mission of enabling millions of people with gait impairments to regain independence.

According to the company, support from the Capital Cell campaign will further accelerate industrialization, expand manufacturing capabilities in Western Switzerland and facilitate first international deployments. Autonomyo’s model reflects a broader shift in rehabilitation toward hybrid care pathways, where clinic-based therapy is complemented by high-intensity, tech-enabled home training.